Eleven Biotherapeutics, Inc. (EBIO) Trading Down 4.3%
Eleven Biotherapeutics, Inc. (NASDAQ:EBIO) shares dropped 4.3% during mid-day trading on Tuesday . The company traded as low as $0.67 and last traded at $0.66. Approximately 818,968 shares were traded during trading, an increase of 81% from the average daily volume of 452,238 shares. The stock had previously closed at $0.69.
The company has a market capitalization of $21.65, a P/E ratio of 4.66 and a beta of 3.29.
A number of institutional investors have recently bought and sold shares of the business. Municipal Employees Retirement System of Michigan acquired a new stake in shares of Eleven Biotherapeutics in the 3rd quarter worth approximately $382,000. Virtu KCG Holdings LLC acquired a new stake in shares of Eleven Biotherapeutics in the 2nd quarter worth approximately $175,000. Spark Investment Management LLC acquired a new stake in shares of Eleven Biotherapeutics in the 2nd quarter worth approximately $148,000. Finally, Vanguard Group Inc. lifted its stake in shares of Eleven Biotherapeutics by 17.4% in the 2nd quarter. Vanguard Group Inc. now owns 206,450 shares of the biopharmaceutical company’s stock worth $324,000 after acquiring an additional 30,600 shares during the period. 4.91% of the stock is owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION WARNING: This piece of content was originally published by Daily Political and is the sole property of of Daily Political. If you are accessing this piece of content on another site, it was stolen and republished in violation of international copyright and trademark law. The correct version of this piece of content can be accessed at https://www.dailypolitical.com/2017/11/21/eleven-biotherapeutics-inc-ebio-trading-down-4-3.html.
Eleven Biotherapeutics Company Profile
Eleven Biotherapeutics, Inc is a preclinical-stage biopharmaceutical company. The Company applies its AMP-Rx platform to the discovery and development of protein therapeutics to treat diseases of the eye. The Company’s product candidate, which is still in preclinical development, is EBI-031, which was designed, engineered and generated using its AMP-Rx platform and are developing as an intravitreal injection for diabetic macular edema (DME) and uveitis.
Receive News & Ratings for Eleven Biotherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eleven Biotherapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.